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npidemiological studies have established that approximately
ne-half of all patients with congestive heart failure have a
reserved ejection fraction (HFpEF). This syndrome pre-
ominantly afflicts older hypertensive individuals. The prev-
lence of HFpEF is increasing (1), paralleling the demo-
raphic shift in the population toward older age. Although
FpEF was previously thought to have a more favorable
ourse than heart failure with reduced ejection fraction
HFrEF), recent studies have shown that the mortality rate
1), the hospital readmission rate (2), and the economic cost
3) of HFpEF rival those of HFrEF.
See pages 402 and 410
The rate of morbidity and mortality of patients with
FrEF has gradually improved during the past 2 decades,
eflecting the impact of several evidence-based interventions
hat have been incorporated into the care of patients with
hronic HFrEF. In contrast, the prognosis of patients with
FpEF has remained steadfastly unchanged during the
ame time period (1), reflecting the dearth of therapeutic
nterventions that have been evaluated in HFpEF, and the
ailure of these therapies to show any benefit on survival in
atients with this syndrome. Thus, there is an urgent need
o develop novel and efficacious strategies for the treatment
f HFpEF, particularly ones that specifically target the
athophysiologic mechanisms that underlie HFpEF.
Several features of the pathophysiology of HFpEF have
een well characterized, including structural and functional
lterations in the heart, such as hypertrophy of the myo-
ytes, changes in the composition of the extracellular matrix,
nd abnormalities in intracellular calcium handling (4).
hese cellular and biochemical alterations likely underlie the
mpaired left ventricular (LV) diastolic relaxation and the
ecreased LV compliance that are observed in HFpEF (5,6).
owever, these diastolic abnormalities are not specific to
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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ging.FpEF; they can be found in patients with HFrEF and in
ypertensive individuals without heart failure (7).
Thus, some investigators (8) have proposed that the
athophysiology of HFpEF may involve additional cardio-
ascular alterations beyond diastolic dysfunction, such as
mpairment in systolic function. Consideration of systolic
unction in patients with HFpEF may appear surprising at
rst because ejection fraction (EF), by definition, should fall
ithin the “normal” range (“preserved” EF). However, it is
mportant to note that EF is only a crude measure of LV
ystolic function, and that it is influenced by several factors
eyond contractility per se, including loading conditions
nd chamber geometry.
Thus, recent studies (9–11) of systolic function in pa-
ients with HFpEF have focused on indices other than EF.
owever, these studies have yielded conflicting results, with
ome reporting abnormalities (9,10), and others observing
o abnormality (11), in systolic function. These inconsistent
ndings could be due, in part, to differences in the popula-
ions being studied or to differences among the various
easures of systolic function that were examined across
tudies.
In this issue of the Journal, Borlaug et al. (12) provide
mportant insights into the systolic function of patients with
FpEF. By using the landmark Rochester Epidemiology
roject, the authors examined 3 groups of subjects: healthy
ontrol patients without cardiovascular disease (n  617),
ypertensive control patients without heart failure (n  719),
nd patients with HFpEF (n  244). The authors noninva-
ively assessed load-independent indexes of chamber-level
ontractility (pre-load recruitable stroke work and wall stress-
orrected endocardial fractional shortening) and of myocardial
ontractility (stress-corrected midwall fractional shortening).
These indexes were greater in the hypertensive than in
he normotensive control groups. In contrast, these indexes
ere lower in patients with HFpEF than in both the
ypertensive and the normotensive control groups. These
ndings indicate that despite the apparently “preserved” EF,
atients with HFpEF exhibit evidence of impaired contrac-
ile function. The strengths of this study include the large
ample size, which makes this by far the largest study that
as evaluated contractility in HFpEF; the nonselected
ature of the study cohort, which avoids the selection and
eferral biases that have plagued many of the small studies of
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hich allows the proper distinction between alterations that
re specific to HFpEF versus those that are simply due to
ypertension. Importantly, because the impairment in con-
ractility in HFpEF is mild, it is unlikely to be the culprit
echanism that underlies the pathogenesis of HFpEF.
nstead, the authors speculate that the impaired contractility
n HFpEF is due to other alterations in myocardial structure
nd function, and that these alterations are the ones that are
esponsible for the transition of a hypertensive heart to a
ailing heart.
In the study by Borlaug et al. (12), all of the cardio-
ascular measures were assessed in the resting state. From
clinical perspective, one of the hallmarks of HFpEF is
hat symptoms are not usually reported at rest, but may
ecome clinically manifest during low levels of exertion
nd may impose marked limitations in exercise tolerance.
nly a handful of studies have investigated the alter-
tions in the cardiovascular response to exercise that
haracterize patients with HFpEF (13–16). In this issue
f the Journal, Phan et al. (17) report their findings from
study of 20 healthy control patients and 37 patients
ith HFpEF who were examined at rest and during
ubmaximal aerobic exercise. Consistent with findings
rom previous studies (15,16,18), patients with HFpEF
ad evidence of chronotropic incompetence during exer-
ise, which manifested as a deficit in their heart rate
eserve. The cardiac creatine phosphate/adenosine
riphosphate ratio, an index of cardiac energetics, was
ssessed in the resting state with 31P magnetic resonance
pectroscopy and was noted to be 27% lower in patients
ith HFpEF than in control patients. Although cardiac
nergetics were not measured during exercise, the authors
peculate that the lower resting values likely denote
mpaired myocardial energy reserves.
In this study, several indices of systolic and diastolic
unction were evaluated with radionuclide ventriculogra-
hy. In the resting state, these indices did not signifi-
antly differ between the 2 groups, whereas during
xercise, some interesting differences were noted. For
xample, the LV active relaxation period, which is the
nergetically demanding stage of early diastole, became
rolonged during exercise in patients with HFpEF, in
ontrast to the control group, in whom it was shortened.
hether this exercise-induced impairment in LV relax-
tion is specific to HFpEF or whether it can be found in
ther hypertensive individuals cannot be ascertained from
his study because a hypertensive control group was not
xamined. During exercise, patients with HFpEF also
xhibited significant deficits in their ability to augment
everal indices of systolic function. However, it should be
oted that these patients exercised at absolute workloads
hat were lower than those of the control group because
he submaximal stage of exercise was defined as the
orkload corresponding to 50% of heart rate reserve.
1The studies by Borlaug et al. (12) and Phan et al. (17)
rovide valuable incremental insights to our understand-
ng of the pathophysiology of HFpEF. However, addi-
ional studies are sorely needed. Some should be directed
t further elucidating the pathophysiologic mechanisms
hat underlie HFpEF, whereas others should focus on
eveloping interventions that target the specific mecha-
isms that have already been identified in patients with
his condition. These patients are burdened by abnormal-
ties in diastolic function, deficits in their exercise reserve,
nd some compromise in their systolic function, as well as
y the failure of the medical community, so far, to
evelop efficacious interventions that improve their mor-
idity and mortality. Given the increasing prevalence of
FpEF, the economic burden it is imposing on society,
he suffering it inflicts on afflicted individuals, and the
ompromise in their quality of life, it is imperative that
linicians, researchers, funding agencies, and policy mak-
rs urgently recognize that HFpEF is a clinical frontier in
he cardiovascular field that is in dire need of attention.
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